OBJECTIVE: Lipin 1 controls fatty acid metabolism in the nucleus as a transcriptional regulator and in the cytosol as an enzyme catalyzing the penultimate step in phosphoglycerol triacylglyceride (TAG) synthesis. We sought to evaluate the effects of lipin 1 on hepatic TAG synthesis and secretion by gain-of-function and loss-of-function approaches. METHODS AND RESULTS: Rates of TAG synthesis were not impaired in hepatocytes isolated from adult lipin 1-deficient (fld) mice and were actually increased in 14-day-old fld mice. Additionally, compared to littermate controls, VLDL-TAG secretion rates were markedly increased in fld mice of both ages. Lipin 1 overexpression did not alter TAG synthesis rates but significantly suppressed VLDL-TAG secretion. The lipin 1-mediated suppression of VLDL-TAG secretion was linked to the peptide motif mediating its transcriptional-regulatory effects. However, the expression of candidate genes required for VLDL assembly and secretion was unaltered by lipin 1 activation or deficiency. Finally, the hepatic expression of lipin 1 was diminished in obese insulin-resistant mice, whereas adenoviral-mediated overexpression of lipin 1 in liver of these mice inhibits VLDL-TAG secretion and improves hepatic insulin signaling. CONCLUSIONS: Collectively, these studies reveal new and unexpected effects of lipin 1 on hepatic TAG metabolism and obesity-related hepatic insulin resistance.
OBJECTIVE:Lipin 1 controls fatty acid metabolism in the nucleus as a transcriptional regulator and in the cytosol as an enzyme catalyzing the penultimate step in phosphoglyceroltriacylglyceride (TAG) synthesis. We sought to evaluate the effects of lipin 1 on hepatic TAG synthesis and secretion by gain-of-function and loss-of-function approaches. METHODS AND RESULTS: Rates of TAG synthesis were not impaired in hepatocytes isolated from adult lipin 1-deficient (fld) mice and were actually increased in 14-day-old fldmice. Additionally, compared to littermate controls, VLDL-TAG secretion rates were markedly increased in fldmice of both ages. Lipin 1 overexpression did not alter TAG synthesis rates but significantly suppressed VLDL-TAG secretion. The lipin 1-mediated suppression of VLDL-TAG secretion was linked to the peptide motif mediating its transcriptional-regulatory effects. However, the expression of candidate genes required for VLDL assembly and secretion was unaltered by lipin 1activation or deficiency. Finally, the hepatic expression of lipin 1 was diminished in obese insulin-resistant mice, whereas adenoviral-mediated overexpression of lipin 1 in liver of these mice inhibits VLDL-TAG secretion and improves hepatic insulin signaling. CONCLUSIONS: Collectively, these studies reveal new and unexpected effects of lipin 1 on hepatic TAG metabolism and obesity-related hepatic insulin resistance.
Authors: Bettina Mittendorfer; Bruce W Patterson; Samuel Klein; Labros S Sidossis Journal: Am J Physiol Endocrinol Metab Date: 2002-12-10 Impact factor: 4.310
Authors: Michelle A Croce; J Christopher Eagon; Lori L LaRiviere; Kevin M Korenblat; Samuel Klein; Brian N Finck Journal: Diabetes Date: 2007-06-11 Impact factor: 9.461
Authors: Kyle S McCommis; Zhouji Chen; Xiaorong Fu; William G McDonald; Jerry R Colca; Rolf F Kletzien; Shawn C Burgess; Brian N Finck Journal: Cell Metab Date: 2015-09-03 Impact factor: 27.287
Authors: George G Schweitzer; Zhouji Chen; Connie Gan; Kyle S McCommis; Nisreen Soufi; Roman Chrast; Mayurranjan S Mitra; Kui Yang; Richard W Gross; Brian N Finck Journal: J Lipid Res Date: 2015-02-26 Impact factor: 5.922
Authors: Jussi Pihlajamäki; Carles Lerin; Paula Itkonen; Tanner Boes; Thomas Floss; Joshua Schroeder; Farrell Dearie; Sarah Crunkhorn; Furkan Burak; Josep C Jimenez-Chillaron; Tiina Kuulasmaa; Pekka Miettinen; Peter J Park; Imad Nasser; Zhenwen Zhao; Zhaiyi Zhang; Yan Xu; Wolfgang Wurst; Hongmei Ren; Andrew J Morris; Stefan Stamm; Allison B Goldfine; Markku Laakso; Mary Elizabeth Patti Journal: Cell Metab Date: 2011-08-03 Impact factor: 27.287
Authors: Kari T Chambers; Zhouji Chen; Ling Lai; Teresa C Leone; Howard C Towle; Anastasia Kralli; Peter A Crawford; Brian N Finck Journal: Mol Metab Date: 2013-05-09 Impact factor: 7.422